Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 3, 2005, Pages 214-224

  Sulkowski, Mark ^a   Wright, Teresa ^b   Rossi, Stephen ^b   Arora, Sanjeev ^b   Lamb, Matthew ^b   Wang, Ka ^b   Gries, Jean Michel ^b   Yalamanchili, Sreeni ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; METHADONE; PEGINTERFERON ALPHA2A; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; INTOXICATION; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NEUTROPHIL; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VIRUS DETECTION;

AREA UNDER CURVE; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MALE; METHADONE; MIDDLE AGED; NEUTROPHILS; POLYETHYLENE GLYCOLS;

EID: 13944258563     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.09.008     Document Type: Article

References (38)

1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease Centers for Disease Control and Prevention MMWR Recomm Rep 47 1998 1 39
2. M.J. Alter Prevention of spread of hepatitis C Hepatology 36 2002 S93 S98
3. R.S. Garfein, D. Vlahov, N. Galai, M.C. Doherty, K.E. Nelson Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses Am J Public Health 86 1996 655 661
4. D.L. Thomas Correlates of hepatitis C virus infections among injection drug users Medicine (Baltimore) 74 1995 212 220
5. D.M. Novick The impact of hepatitis C virus infection on methadone maintenance treatment Mt Sinai J Med 67 2000 437 443
6. B.R. Edlin Prevention and treatment of hepatitis C in injection drug users Hepatology 36 2002 S210 S219
7. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002 Hepatology 36 2002 S3 S20
8. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
9. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
10. S.J. Hadziyannis, H. Sette Jr, T.R. Morgan, V. Balan, M. Diago, P. Marcellin Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
11. S. Zeuzem, M. Diago, E. Gane, K.R. Reddy, P. Pockros, D. Prati Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 127 2004 1724 1732
12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
13. D.B. Strader Understudied populations with hepatitis C Hepatology 36 2002 S226 S236
14. K. Wolff, A. Rostami-Hodjegan, S. Shires, A.W. Hay, M. Feely, R. Calvert The pharmacokinetics of methadone in healthy subjects and opiate users Br J Clin Pharmacol 44 1997 325 334
15. D.J. Foster, A.A. Somogyi, K.R. Dyer, J.M. White, F. Bochner Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients Br J Clin Pharmacol 50 2000 427 440
16. D.J. Foster, A.A. Somogyi, J.M. White, F. Bochner Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients Br J Clin Pharmacol 57 2004 742 755
17. D.W. Boulton, P. Arnaud, C.L. DeVane Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate Clin Pharmacol Ther 70 2001 48 57
18. J.S. Wang, C.L. DeVane Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro Drug Metab Dispos 31 2003 742 747
19. S. Begre, U. von Bardeleben, D. Ladewig, S. Jaquet-Rochat, L. Cosendai-Savary, K.P. Golay Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers J Clin Psychopharmacol 22 2002 211 215
20. B.C. Israel, R.A. Blouin, W. McIntyre, S.I. Shedlofsky Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients Br J Clin Pharmacol 36 1993 229 235
21. Y. Horsmans, R. Brenard, A.P. Geubel Short report: interferon-alpha decreases 14C-aminopyrine breath test values in patients with chronic hepatitis C Aliment Pharmacol Ther 8 1994 353 355
22. G.P. Pageaux, Y. le Bricquir, F. Berthou, N. Bressot, M.C. Picot, F. Blanc Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C Eur J Gastroenterol Hepatol 10 1998 491 495
23. M. Islam, R.F. Frye, T.J. Richards, I. Sbeitan, S.S. Donnelly, P. Glue Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs Clin Cancer Res 8 2002 2480 2487
24. J.C. Duclos-Vallee, M. Nishioka, N. Hosomi, K. Arima, A. Leclercq, J.F. Bach Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection J Hepatol 28 1998 965 970
25. G.N. Dalekos, H. Wedemeyer, P. Obermayer-Straub, A. Kayser, A. Barut, H. Frank Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment J Hepatol 30 1999 366 375
26. L. Becquemont, O. Chazouilleres, L. Serfaty, J.M. Poirier, F. Broly, P. Jaillon Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C Clin Pharmacol Ther 71 2002 488 495
27. W.F. Geber, S.S. Lefkowitz, C.Y. Hung Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum interferon level in response to viral infection Arch Int Pharmacodyn Ther 214 1975 322 327
28. D.I. Quinn, A. Wodak, R.O. Day Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users Clin Pharmacokinet 33 1997 344 400
29. M.W. Modi, M. Fried, R.W. Reindollar, V.R. Rustgi, R. Kenny, T.L. Wright The pharmacokinetic behavior of pegylated (40KDA) interferon alfa-2a (Pegasys) in chronic hepatitis C patients after multiple dosing [abstract] Hepatology 32 2000 394A
30. N.E. Martin, M.W. Modi, R. Reddy Characterization of pegylated (40KDA) interferon alfa-2a (Pegasys) in the elderly [abstract] Hepatology 32 2000 348A
31. Z.-X. Xu, J. Hoffman, I. Patel, P. Joubert Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon alfa-2a (IFN alfa-2a) to healthy subjects [abstract] Hepatology 28 1998 702A
32. C.M. Perry, B. Jarvis Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C Drugs 61 2001 2263 2288
33. Yan S. Clinical study report - Protocol NP16569: A comparability study of peginterferon (40kDa) alfa-2a of clinical trial material and the commercial product administered subcutaneously via needle injection in healthy subjects. Nutley (NJ): Roche; 2002 Mar 29. Research report 1007463.
34. S. Zeuzem, E. Herrmann, J.H. Lee, J. Fricke, A.U. Neumann, M. Modi Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a Gastroenterology 120 2001 1438 1447
35. S. Zeuzem, V. Feinman, J. Rasenack, E.J. Heathcote, M.Y. Lai, E. Gane Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666 1672
36. D.H. Van Thiel, A. Anantharaju, S. Creech Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse Am J Gastroenterol 98 2003 2281 2288
37. D.L. Sylvestre Treating hepatitis C in methadone maintenance patients: an interim analysis Drug Alcohol Depend 67 2002 117 123
38. M. Backmund, K. Meyer, M. Von Zielonka, D. Eichenlaub Treatment of hepatitis C infection in injection drug users Hepatology 34 2001 188 193